An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease from CTAD 2015
The 8th annual meeting of Clinical Trials on Alzheimer’s Disease (CTAD) was held in Barcelona, Spain, November 5-7, 2015. CTAD has become one of the most important scientific meetings in the Alzheimer’s disease (AD) area. It brings together today’s worldwide leaders in AD to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of AD treatments. In this activity, 2 experts summarize the key learnings from this year’s conference.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with AD.
Upon completion of this activity, participants will be better able to:
Discuss recent advances in clinical trials of AD
Identify immunotherapies in development for the treatment of AD
Analyze the use of biomarkers to identify patients with early-stage AD
Marwan Sabbagh, MD, FAAN, CCRI
Stephen Salloway, MD, MS
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Marwan Sabbagh, MD, FAAN, CCRI||Consultant/Advisor: Biogen, Inc.|
|Stephen Salloway, MD, MS|
Consultant/Advisor: Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Ltd, Genentech, Inc., Merck & Co., Inc.
Grant/Research Support: AVID Center, Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Ltd, Functional Neuromodulation, Genentech, Inc., Merck & Co.
Non-faculty: Sandy Breslow; Bernard Abrams, MD; Alison Kemp; Lyerka Miller, PhD; Melanie Spurgeon; and Kim Sponza, hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This CME activity is supported by an independent educational grant from Biogen, Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
Course Open Date: January 12, 2016 | Course Expiration Date: January 11, 2017
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, and Biogen, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Non-physician